Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR

Nature Chemical Biology

Volumn 8, Issue 8, 2012, Pages 725-730

  Ersoy, Baran A ^a,b,f   Pardo, Leonardo ^c   Zhang, Sumei ^a,b   Thompson, Darren A ^d,g   Millhauser, Glenn ^d   Govaerts, Cedric ^e   Vaisse, Christian ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; G PROTEIN COUPLED RECEPTOR; MELANOCORTIN 4 RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL STRAIN HEK293; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; NERVE CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECRETION; RECEPTOR BINDING;

AGOUTI;

EID: 84864290272     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1008     Document Type: Article

References (40)

1. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: Molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 103, 21-80 (2004).
2. Kobilka, B.K. G protein-coupled receptor structure and activation. Biochim. Biophys. Acta 1768, 794-807 (2007).
3. Lagerström, M.C. & Schiöth, H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357 (2008).
4. Scarborough, R.M. et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem. 267, 13146-13149 (1992).
5. Vassart, G., Pardo, L. & Costagliola, S. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem. Sci. 29, 119-126 (2004).
6. Breit, A. et al. Alternative G protein coupling and biased agonism: New insights into melanocortin-4 receptor signalling. Mol. Cell. Endocrinol. 331, 232-240 (2011).
7. Bromberg, Y., Overton, J., Vaisse, C., Leibel, R.L. & Rost, B. In silico mutagenesis: A case study of the melanocortin 4 receptor. FASEB J. 23, 3059-3069 (2009).
8. Srinivasan, S. et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114, 1158-1164 (2004).
9. Seifert, R. & Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptors: Cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381-416 (2002).
10. Tolle, V. & Low, M.J. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin- deficient mice. Diabetes 57, 86-94 (2008).
11. Peter, J.C. et al. Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R2151-R2158 (2007).
12. Ollmann, M.M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278, 135-138 (1997).
13. Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J. & Cone, R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385, 165-168 (1997).
14. Nijenhuis, W.A., Oosterom, J. & Adan, R.A. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 15, 164-171 (2001).
15. Chai, B.X. et al. Inverse agonist activity of agouti and agouti-related protein. Peptides 24, 603-609 (2003).
16. Costa, T. & Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA 86, 7321-7325 (1989).
17. Kenakin, T. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2-11 (2004).
18. Patel, M.P. et al. Loop-swapped chimeras of the agouti-related protein and the agouti signaling protein identify contacts required for melanocortin 1 receptor selectivity and antagonism. J. Mol. Biol. 404, 45-55 (2010).
19. Ballesteros, J.A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
20. Lubrano-Berthelier, C. et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: Prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J. Clin. Endocrinol. Metab. 91, 1811-1818 (2006).
21. Calton, M.A. et al. Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum. Mol. Genet. 18, 1140-1147 (2009).
22. Haskell-Luevano, C., Cone, R.D., Monck, E.K. & Wan, Y.P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: Identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 40, 6164-6179 (2001).
23. Jongejan, A. et al. Linking ligand binding to histamine H1 receptor activation. Nat. Chem. Biol. 1, 98-103 (2005).
24. Pellissier, L.P. et al. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-HT4 receptors. Mol. Pharmacol. 75, 982-990 (2009).
25. Holst, B. et al. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J. Biol. Chem. 285, 3973-3985 (2010).
26. Choe, H.W. et al. Crystal structure of metarhodopsin II. Nature 471, 651-655 (2011).
27. Standfuss, J. et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656-660 (2011).
28. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011).
29. Warne, T. et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469, 241-244 (2011).
30. Rasmussen, S.G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175-180 (2011).
31. Rosenbaum, D.M. et al. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 469, 236-240 (2011).
32. Shi, L. et al. β2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277, 40989-40996 (2002).
33. Swaminath, G. et al. Probing the 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280, 22165-22171 (2005).
34. Civelli, O. GPCR deorphanizations: The novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26, 15-19 (2005).
35. Bond, R.A. & Ijzerman, A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27, 92-96 (2006).
36. Chen, G. et al. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol. Pharmacol. 57, 125-134 (2000).
37. Behan, D.P. & Chalmers, D.T. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr. Opin. Drug Discov. Devel. 4, 548-560 (2001).
38. Toyooka, M., Tujii, T. & Takeda, S. The N-terminal domain of GPR61, an orphan G-protein-coupled receptor, is essential for its constitutive activity. J. Neurosci. Res. 87, 1329-1333 (2009).
39. Lubrano-Berthelier, C. et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum. Mol. Genet. 12, 145-153 (2003).
40. Vaisse, C. et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253-262 (2000).